Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…
HOME > LATEST
LATEST
-
ORGANIZATION Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
-
BUSINESS Japan’s First CAD Therapy, Enjaymo, Now Available: Sanofi
September 9, 2022
-
BUSINESS Japan Ethical Drug Sales Up 0.8% in July: Crecon
September 9, 2022
-
BUSINESS Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
-
ACADEMIA University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
-
REGULATORY Guardians Now Urged to Get Kids Ages 5-11 Vaccinated against COVID-19
September 8, 2022
-
ORGANIZATION JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
-
BUSINESS Samsca Generics Get Additional Indication for Heart Failure, AG Too
September 8, 2022
-
REGULATORY LDP Group Urges Thorough Discussions on New Data for Shionogi COVID Pill Once Out
September 8, 2022
-
BUSINESS AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
-
BUSINESS AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
-
REGULATORY Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
-
BUSINESS Promotions via In-Hospital Seminars, Webinars Record Two-Digit Rise YOY in July: Intage
September 7, 2022
-
ORGANIZATION Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
-
REGULATORY Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
-
BUSINESS Sysmex Files Gene Profiling Test as CDx for Taiho’s Futibatinib
September 7, 2022
-
BUSINESS Opdivo Best-Selling Drug in Japan for 8 Months on End: Encise
September 7, 2022
-
BUSINESS Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
-
REGULATORY Ultrasound Dementia Therapy Machine in Line for First Sakigake Device Designation, Japan Submission Eyed in 2025
September 6, 2022
-
REGULATORY MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…